Vaxart's oral COVID-19 vaccine shows broad effectiveness in early trials

By The Science Advisory Board staff writers

May 4, 2021 -- Vaxart said that new phase I clinical trial data demonstrate that its VXA-CoV2-1 oral COVID-19 tablet vaccine yields broad cross-coronavirus activity.

The vaccine showed substantial CD8+ T-cell responses, as measured by interferon-gamma and tumor necrosis factor-alpha induction, according to the company. What's more, a comparative experiment conducted by Vaxart found that volunteers who had received the Moderna or Pfizer messenger RNA (mRNA) vaccines had fewer T-cell responses than those who were given the VXA-CoV2-1 vaccine, Vaxart said.

The firm noted that the vaccine candidate also triggered specific mucosal immunoglobulin A antibodies that appeared to be cross-reactive against other coronaviruses such as SARS-CoV, MERS-CoV, and the endemic common cold viruses 229E, NL63, HKU1, and OC43. It also includes both the spike and nucleocapsid SARS-CoV-2 proteins.

Vaxart's oral COVD-19 vaccine is promising in early data
Vaxart announced positive preliminary data from its phase I clinical trial evaluating VXA-CoV2-1, its oral COVID-19 tablet vaccine.
Centaur Biopharma to manufacture COVID-19 vaccine for Vaxart
Centaur Biopharmaceutical Services has expanded its manufacturing agreement with Vaxart to manufacture Vaxart's oral COVID-19 vaccine.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter